Tg Therapeutics Inc Financials
This page shows Tg Therapeutics Inc (TGTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Tg Therapeutics Inc has an operating margin of 20.0%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 67/100, reflecting efficient cost management and pricing power. This is up from 12.7% the prior year.
Tg Therapeutics Inc's revenue surged 87.3% year-over-year to $616.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Tg Therapeutics Inc carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.10, Tg Therapeutics Inc holds $4.10 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 81/100.
While Tg Therapeutics Inc generated -$24.8M in operating cash flow, capex of $214K consumed most of it, leaving -$25.0M in free cash flow. This results in a low score of 15/100, reflecting heavy capital investment rather than weak cash generation.
Tg Therapeutics Inc earns a strong 69.0% return on equity (ROE), meaning it generates $69 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 10.5% the prior year.
Tg Therapeutics Inc scores 7.82, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.4B) relative to total liabilities ($415.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Tg Therapeutics Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Tg Therapeutics Inc generates $-0.06 in operating cash flow (-$24.8M OCF vs $447.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Tg Therapeutics Inc earns $4.6 in operating income for every $1 of interest expense ($123.3M vs $26.7M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Tg Therapeutics Inc generated $616.3M in revenue in fiscal year 2025. This represents an increase of 87.3% from the prior year.
Tg Therapeutics Inc's EBITDA was $123.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 193.8% from the prior year.
Tg Therapeutics Inc reported $447.2M in net income in fiscal year 2025. This represents an increase of 1812.4% from the prior year.
Tg Therapeutics Inc earned $2.77 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1746.7% from the prior year.
Cash & Balance Sheet
Tg Therapeutics Inc generated -$25.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 38.4% from the prior year.
Tg Therapeutics Inc held $79.1M in cash against $245.6M in long-term debt as of fiscal year 2025.
Tg Therapeutics Inc had 155M shares outstanding in fiscal year 2025. This represents a decrease of 0.3% from the prior year.
Margins & Returns
Tg Therapeutics Inc's gross margin was 83.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.6 percentage points from the prior year.
Tg Therapeutics Inc's operating margin was 20.0% in fiscal year 2025, reflecting core business profitability. This is up 7.3 percentage points from the prior year.
Tg Therapeutics Inc's net profit margin was 72.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 65.5 percentage points from the prior year.
Tg Therapeutics Inc's ROE was 69.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 58.5 percentage points from the prior year.
Capital Allocation
Tg Therapeutics Inc invested $160.2M in research and development in fiscal year 2025. This represents an increase of 69.9% from the prior year.
Tg Therapeutics Inc spent $91.2M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 941.6% from the prior year.
Tg Therapeutics Inc invested $214K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 375.6% from the prior year.
TGTX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192.6M+19.1% | $161.7M+14.6% | $141.1M+16.8% | $120.9M+11.7% | $108.2M+29.0% | $83.9M+14.2% | $73.5M+15.7% | $63.5M |
| Cost of Revenue | $38.1M+35.8% | $28.1M+48.3% | $18.9M+21.9% | $15.5M+0.9% | $15.4M+64.9% | $9.3M+12.5% | $8.3M+52.6% | $5.4M |
| Gross Profit | $154.4M+15.6% | $133.6M+9.3% | $122.2M+16.0% | $105.3M+13.5% | $92.8M+24.5% | $74.5M+14.4% | $65.2M+12.3% | $58.0M |
| R&D Expenses | $41.2M+0.8% | $40.9M+28.6% | $31.8M-31.4% | $46.4M+94.2% | $23.9M+18.6% | $20.1M+14.7% | $17.6M-46.3% | $32.7M |
| SG&A Expenses | $62.7M-1.0% | $63.4M+14.0% | $55.6M+10.4% | $50.3M+29.2% | $39.0M-7.2% | $42.0M+8.2% | $38.8M+12.2% | $34.6M |
| Operating Income | $50.5M+72.0% | $29.4M-15.7% | $34.8M+304.1% | $8.6M-71.2% | $29.9M+140.9% | $12.4M+41.0% | $8.8M+195.1% | -$9.3M |
| Interest Expense | $6.5M-2.8% | $6.7M+0.1% | $6.7M-0.6% | $6.8M-2.5% | $6.9M-36.0% | $10.8M+172.4% | $4.0M+73.8% | $2.3M |
| Income Tax | $22.1M+106.0% | -$365.0M-13454.8% | $2.7M+569.9% | $408K-80.8% | $2.1M+446.9% | $388K+218.3% | -$328K-1231.0% | $29K |
| Net Income | $23.0M-94.1% | $390.9M+1286.8% | $28.2M+457.1% | $5.1M-78.3% | $23.3M+501.3% | $3.9M-43.6% | $6.9M+164.2% | -$10.7M |
| EPS (Diluted) | N/A | $2.43+1329.4% | $0.17+466.7% | $0.03 | N/A | $0.02-50.0% | $0.04+157.1% | $-0.07 |
TGTX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B+3.7% | $1.0B+45.9% | $702.6M+7.0% | $656.7M+13.7% | $577.7M-1.4% | $586.0M+46.1% | $401.2M+7.5% | $373.3M |
| Current Assets | $630.8M+5.2% | $599.8M-9.7% | $664.0M+3.0% | $644.5M+13.8% | $566.4M-1.3% | $574.1M+47.5% | $389.1M+7.9% | $360.6M |
| Cash & Equivalents | $79.1M+6.8% | $74.1M-42.6% | $129.1M-2.3% | $132.1M-26.5% | $179.9M-8.1% | $195.8M+136.2% | $82.9M+9.8% | $75.5M |
| Inventory | $125.6M-14.5% | $147.0M-5.3% | $155.2M-1.6% | $157.8M+42.8% | $110.5M+30.5% | $84.7M+4.2% | $81.2M+4.5% | $77.7M |
| Accounts Receivable | $305.6M+15.2% | $265.4M+14.6% | $231.5M+21.8% | $190.1M+47.2% | $129.2M+11.6% | $115.7M+38.4% | $83.6M+28.7% | $65.0M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $799K |
| Total Liabilities | $415.2M-0.6% | $417.8M-2.0% | $426.2M+1.6% | $419.4M+18.0% | $355.3M-9.8% | $393.9M+76.1% | $223.6M+4.9% | $213.2M |
| Current Liabilities | $153.8M-1.9% | $156.8M-8.8% | $171.9M+7.3% | $160.2M+76.7% | $90.7M-27.5% | $125.1M+15.1% | $108.7M+9.0% | $99.7M |
| Long-Term Debt | $245.6M+0.1% | $245.3M+0.1% | $245.0M+0.1% | $244.7M+0.1% | $244.4M+0.1% | $244.2M+138.1% | $102.5M+1.2% | $101.3M |
| Total Equity | $648.0M+6.7% | $607.2M+119.7% | $276.4M+16.5% | $237.3M+6.7% | $222.4M+15.7% | $192.2M+8.2% | $177.6M+10.9% | $160.1M |
| Retained Earnings | -$1.1B+2.1% | -$1.1B+26.1% | -$1.5B+1.8% | -$1.5B+0.3% | -$1.5B+1.5% | -$1.6B+0.2% | -$1.6B-2.1% | -$1.5B |
TGTX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.7M+184.9% | -$23.2M-411.4% | $7.4M+125.9% | -$28.7M-12.0% | -$25.6M-110.1% | -$12.2M-320.5% | $5.5M+167.5% | -$8.2M |
| Capital Expenditures | $67K-16.3% | $80K+90.5% | $42K+68.0% | $25K+19.0% | $21K-12.5% | $24K | $0 | $0 |
| Free Cash Flow | $19.6M+184.3% | -$23.2M-414.2% | $7.4M+125.7% | -$28.7M-12.0% | -$25.7M-109.8% | -$12.2M-320.9% | $5.5M+167.5% | -$8.2M |
| Investing Cash Flow | -$15.6M-133.7% | $46.4M+1261.4% | -$4.0M+69.1% | -$12.9M-181.9% | $15.8M+269.1% | -$9.3M-628.8% | $1.8M+119.1% | -$9.3M |
| Financing Cash Flow | $1.1M+101.4% | -$78.2M-1114.4% | -$6.4M-5.6% | -$6.1M-0.5% | -$6.1M-104.5% | $134.5M+99495.6% | $135K+1250.0% | $10K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0-100.0% | $78.2M+1038.1% | $6.9M+12.3% | $6.1M-7.4% | $6.6M+207.6% | $2.1M | $0 | $0 |
TGTX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.2%-2.4pp | 82.6%-3.9pp | 86.6%-0.6pp | 87.1%+1.4pp | 85.8%-3.1pp | 88.9%+0.2pp | 88.7%-2.7pp | 91.4% |
| Operating Margin | 26.2%+8.1pp | 18.2%-6.5pp | 24.7%+17.6pp | 7.1%-20.5pp | 27.7%+12.9pp | 14.8%+2.8pp | 12.0%+26.6pp | -14.6% |
| Net Margin | 12.0%-229.8pp | 241.7%+221.8pp | 20.0%+15.8pp | 4.2%-17.4pp | 21.6%+16.9pp | 4.6%-4.7pp | 9.4%+26.2pp | -16.9% |
| Return on Equity | 3.5%-60.8pp | 64.4%+54.2pp | 10.2%+8.1pp | 2.1%-8.4pp | 10.5%+8.5pp | 2.0%-1.8pp | 3.9%+10.6pp | -6.7% |
| Return on Assets | 2.2%-36.0pp | 38.1%+34.1pp | 4.0%+3.2pp | 0.8%-3.3pp | 4.0%+3.4pp | 0.7%-1.1pp | 1.7%+4.6pp | -2.9% |
| Current Ratio | 4.10+0.3 | 3.82-0.0 | 3.86-0.2 | 4.02-2.2 | 6.25+1.7 | 4.59+1.0 | 3.58-0.0 | 3.62 |
| Debt-to-Equity | 0.38-0.0 | 0.40-0.5 | 0.89-0.1 | 1.03-0.1 | 1.10-0.2 | 1.27+0.7 | 0.58-0.1 | 0.63 |
| FCF Margin | 10.2%+24.5pp | -14.4%-19.6pp | 5.2%+29.0pp | -23.8%-0.1pp | -23.7%-9.1pp | -14.6%-22.1pp | 7.5%+20.5pp | -12.9% |
Similar Companies
Frequently Asked Questions
What is Tg Therapeutics Inc's annual revenue?
Tg Therapeutics Inc (TGTX) reported $616.3M in total revenue for fiscal year 2025. This represents a 87.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Tg Therapeutics Inc's revenue growing?
Tg Therapeutics Inc (TGTX) revenue grew by 87.3% year-over-year, from $329.0M to $616.3M in fiscal year 2025.
Is Tg Therapeutics Inc profitable?
Yes, Tg Therapeutics Inc (TGTX) reported a net income of $447.2M in fiscal year 2025, with a net profit margin of 72.6%.
What is Tg Therapeutics Inc's EBITDA?
Tg Therapeutics Inc (TGTX) had EBITDA of $123.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Tg Therapeutics Inc have?
As of fiscal year 2025, Tg Therapeutics Inc (TGTX) had $79.1M in cash and equivalents against $245.6M in long-term debt.
What is Tg Therapeutics Inc's gross margin?
Tg Therapeutics Inc (TGTX) had a gross margin of 83.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Tg Therapeutics Inc's operating margin?
Tg Therapeutics Inc (TGTX) had an operating margin of 20.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Tg Therapeutics Inc's net profit margin?
Tg Therapeutics Inc (TGTX) had a net profit margin of 72.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Tg Therapeutics Inc's return on equity (ROE)?
Tg Therapeutics Inc (TGTX) has a return on equity of 69.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tg Therapeutics Inc's free cash flow?
Tg Therapeutics Inc (TGTX) generated -$25.0M in free cash flow during fiscal year 2025. This represents a 38.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tg Therapeutics Inc's operating cash flow?
Tg Therapeutics Inc (TGTX) generated -$24.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Tg Therapeutics Inc's total assets?
Tg Therapeutics Inc (TGTX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tg Therapeutics Inc's capital expenditures?
Tg Therapeutics Inc (TGTX) invested $214K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tg Therapeutics Inc spend on research and development?
Tg Therapeutics Inc (TGTX) invested $160.2M in research and development during fiscal year 2025.
What is Tg Therapeutics Inc's current ratio?
Tg Therapeutics Inc (TGTX) had a current ratio of 4.10 as of fiscal year 2025, which is generally considered healthy.
What is Tg Therapeutics Inc's debt-to-equity ratio?
Tg Therapeutics Inc (TGTX) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tg Therapeutics Inc's return on assets (ROA)?
Tg Therapeutics Inc (TGTX) had a return on assets of 42.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Tg Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Tg Therapeutics Inc (TGTX) had $79.1M in cash against an annual operating cash burn of $24.8M. This gives an estimated cash runway of approximately 38 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Tg Therapeutics Inc's Altman Z-Score?
Tg Therapeutics Inc (TGTX) has an Altman Z-Score of 7.82, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Tg Therapeutics Inc's Piotroski F-Score?
Tg Therapeutics Inc (TGTX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tg Therapeutics Inc's earnings high quality?
Tg Therapeutics Inc (TGTX) has an earnings quality ratio of -0.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Tg Therapeutics Inc cover its interest payments?
Tg Therapeutics Inc (TGTX) has an interest coverage ratio of 4.6x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Tg Therapeutics Inc?
Tg Therapeutics Inc (TGTX) scores 76 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.